98%
921
2 minutes
20
MicroRNA (miRNA)-based therapy holds significant potential; however, its structural limitations pose a challenge to the full exploitation of its biomedical functionality. Framework nucleic acids are promising owing to their transportability, biocompatibility, and functional editability. MiRNA-125 is embedded into a nucleic acid framework to create an enzyme-responsive nanoparachute (NP), enhancing the miRNA loading capacity while preserving the attributes of small-scale framework nucleic acids and circumventing the uncertainty related to RNA exposure in conventional loading methods. An enzyme-sensitive sequence is designed in NP as a bioswitchable apparatus for cargo miRNAs release. NP is compared with conventional delivery modes and delivery vehicles, confirming its excellent transportability and sustained release properties. Moreover, NP confers good enzyme and serum resistance to the cargo miRNAs. Simultaneously, it can easily deliver miRNA-125 to liver and kidney lesions owing to its passive targeting properties. This allows for Keap1/Nrf2 pathway regulation and p53 protein targeting in the affected tissues. Additionally, NP negatively regulates the expression of Bax and Caspase-3. These combined actions help to inhibit oxidation, prevent cell cycle arrest, and reduce the apoptosis of liver and kidney cells. Consequently, this strategy offers a potential treatment for acute liver and kidney injury.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905073 | PMC |
http://dx.doi.org/10.1002/advs.202411210 | DOI Listing |
Arch Anim Nutr
September 2025
Department Safety in the Food Chain, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Copper (Cu) supplementation is essential in pig nutrition; however, its effects on performance, trace element accumulation in edible tissues, and environmental excretion require careful evaluation. In the present study a total of 24 male, castrated fattening pigs of two different hybrid mast lines (11 weeks of age) were divided according to their initial body weight (25.8 ± 3.
View Article and Find Full Text PDFTransplant Direct
September 2025
Immunopathology Laboratory, Germans Trias I Pujol Research Institute, Badalona, Catalonia, Spain.
One of the major hurdles in solid organ transplantation is graft rejection, which must be prevented with lifelong general immunosuppression. However, modern maintenance immunosuppression is accompanied by serious side effects, such as an increased risk of infection and malignancies. The search for alternative therapies specifically controlling allogeneic responses is fueling renewed interest in extracorporeal photopheresis (ECP).
View Article and Find Full Text PDFAquac Nutr
August 2025
Guangdong Provincial Key Laboratories of Marine Biotechnology, Shantou University, Shantou 515063, China.
In mammals, cholesterol accumulation in tissues often results in health damage, such as oxidative stress. In contrast, the adverse effects of cholesterol accumulation on the physiological health of fish remain largely unexplored. The present study investigated the impacts of cholesterol accumulation on oxidative stress and the potential mechanisms involved in Nile tilapia ().
View Article and Find Full Text PDFFront Chem
August 2025
Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Jinan University, Guangzhou, China.
Introduction: Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects. Erianin, a natural compound from Chinese medicine Lindl, demonstrates significant potential in both tumor growth inhibition and chemotherapy toxicity reduction.
View Article and Find Full Text PDFCureus
August 2025
Dermatology, Hôpital Privé Francheville, Perigueux, FRA.
Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy.
View Article and Find Full Text PDF